A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the T ...
A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies - Sirolimus for intractable vascular anomalies A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the T ...
Body surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. Body surface area (BSA) >= 1.0m2: an initial dose of sirolimus(2mg/day) is single orally administere ...
French National Cohort of Children With Port Wine Stain
French National Prospective Cohort of Children With Port Wine Stain on a Limb = Cohorte Nationale d'Enfants Avec Angiome Plan de Membre inférieur French National Prospective Cohort of Children With Port Wine Stain on a Limb = Cohorte Nationale d' ...
Port Wine Stain;Klippel Trenaunay Syndrome;Parkes Weber Syndrome